Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia
Citations Over TimeTop 10% of 2016 papers
Abstract
The antipsychotic clozapine is uniquely effective in the management of schizophrenia; however, its use is limited by its potential to induce agranulocytosis. The causes of this, and of its precursor neutropenia, are largely unknown, although genetic factors have an important role. We sought risk alleles for clozapine-associated neutropenia in a sample of 66 cases and 5583 clozapine-treated controls, through a genome-wide association study (GWAS), imputed human leukocyte antigen (HLA) alleles, exome array and copy-number variation (CNV) analyses. We then combined associated variants in a meta-analysis with data from the Clozapine-Induced Agranulocytosis Consortium (up to 163 cases and 7970 controls). In the largest combined sample to date, we identified a novel association with rs149104283 (odds ratio (OR)=4.32, P=1.79 × 10-8), intronic to transcripts of SLCO1B3 and SLCO1B7, members of a family of hepatic transporter genes previously implicated in adverse drug reactions including simvastatin-induced myopathy and docetaxel-induced neutropenia. Exome array analysis identified gene-wide associations of uncommon non-synonymous variants within UBAP2 and STARD9. We additionally provide independent replication of a previously identified variant in HLA-DQB1 (OR=15.6, P=0.015, positive predictive value=35.1%). These results implicate biological pathways through which clozapine may act to cause this serious adverse effect.
Related Papers
- → A 12‐month follow‐up study of treating overweight schizophrenic patients with aripiprazole(2008)15 cited
- → Aripiprazole-induced Asymptomatic Hypertension: A Case Report(2025)12 cited
- → Suppression of antipsychotic-induced tardive dyskinesia with aripiprazole in an elderly patient with bipolar I disorder(2013)3 cited
- Effect of aripiprazole on life quality in schizophrenics:Meta-analysis(2008)
- 統合失調症患者に対するaripiprazole持続性注射剤の安全性と有効性:製造販売後調査の中間解析結果(ALISE study)(2018)